GYY4137 is a slow-releasing hydrogen sulfide (H₂S) donor with vasodilatory and antihypertensive activities; it also exhibits anti-inflammatory and anticancer properties. It induces concentration-dependent cytotoxicity in various human cancer cell lines (HeLa, HCT-116, HepG2, HL-60, MCF-7, MV4-11, and U2OS) without affecting normal human lung fibroblasts (IMR90, WI-38). GYY4137 suppresses LPS-induced production of nitrite (NO₂⁻), PGE₂, TNF-α, and IL-6 in human fibroblast-like synoviocytes (HFLS) and articular chondrocytes (HAC), downregulates the expression and catalytic activity of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and inhibits LPS-induced NF-κB activation. In vivo, GYY4137 significantly reduces tumor volume in xenograft models in a dose-dependent manner, inhibits tumor growth in a subcutaneous HepG2 xenograft model by suppressing STAT3 activation and its target gene expression, and demonstrates anti-inflammatory effects by reducing synovial fluid myeloperoxidase (MPO) and N-acetyl-β-D-glucosaminidase (NAG) activity as well as decreasing TNF-α, IL-1β, IL-6, and IL-8 levels. Additionally, GYY4137 prevents nitrosative stress and α-synuclein nitration in an MPTP-induced mouse model of Parkinson’s disease.